Abstract:5688 CRM1 is an essential protein required to export a set of ‘cargo’ proteins which bear a leucine-rich nuclear export sequence (NES) from the nucleus to the cytoplasm. Examples of cancer-related proteins bearing CRM1-dependent NESs include p53, BCR-Abl, and FOXO-3a. Nuclear sequestration of these CRM1 ‘cargo’ proteins upon inhibition of CRM1 can lead to cell growth inhibition in normal cells or apoptosis in cancer cells. The identification of CRM1 as a novel target in cancer came from the study of Leptomycin B (LMB) and its analogs. These molecules are potent cytotoxic agents which belong to a group of polyketide natural products known as nuclear export inhibitors (NEIs). LMB and its analogs covalently bind to the nuclear exportin CRM1 and thereby inhibit its ability to shuttle cargo proteins to the cytoplasm. The development of LMB was limited by the significant toxicity observed in previous studies (Newlands, et al., 1996, Br. J. Can., 74: 648-649). We have recently developed a series of NEI analogs with significantly improved biological and pharmacological properties over LMB. Upon examination of the activity of these molecules in leukemia cell lines, we found that NEIs were very potent in vitro in ALL (Molt-4, CCRF-CEM, Jurkat) and AML (MV-4-11) cell lines. Exposure to NEIs led to a rapid and dramatic induction of multiple markers of apoptosis (caspases, Annexin V binding). Based on these results, we examined the activity of two NEI analogs, KOS-1815 and KOS-2464, in murine leukemia xenograft models. Both of these drugs, when dosed on a weekly schedule, significantly inhibited the growth of MV-4-11 (T/C = ~22% for KOS-2464 and ~26% for KOS-1815) and Molt-4 (T/C = ~38% for KOS-2464 and ~29% for KOS-1815) xenografts. In addition, a single administration of KOS-2464 or KOS-1815 induced regression of large (>1000 mm3) CCRF-CEM xenografts. KOS-2464 was very well-tolerated at efficacious doses in all of these leukemia models, while KOS-1815 induced a ~5 to 10% transient body weight loss upon dosing. Finally, we established a Molt-4 orthotopic leukemia model in mice. Weekly dosing of KOS-1815 and KOS-2464 for three weeks, beginning eight days after cancer cell implantation, doubled survival of these leukemic mice. Median survival increased from 25 days for the control group to 50+ days for the drug-treated groups (56 days for KOS-2464 and 50 days for KOS-1815). Studies are ongoing to gain further insight into the mechanism by which these molecules exert their activity in leukemia models. Taken together, the current study shows that KOS-2464, our lead NEI analog, with its novel mechanism of action and wide therapeutic window, has significant potential as a novel anti-cancer agent, especially for the treatment of leukemia.

Ciclopirox olamine sensitizes leukemia cells to natural killer cell-mediated cytolysis by upregulating NKG2DLs via the Akt signaling pathway

Ciclopirox Olamine Exerts Tumor-Suppressor Effects Via Topoisomerase II Alpha in Lung Adenocarcinoma.

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells

Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway

Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines

The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway

Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA/ROCK1/PTEN/PI3K/Akt pathway-mediated mitochondrial translocation of cofilin

Cytotoxic activity of lithospermum erythrorhizon root extract against childhood acute leukemia cells via regulation of PI3K/AKT/mTOR pathway

Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer

Ciclopirox platinum(IV) conjugates suppress tumors by promoting mitophagy and provoking immune responses

Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation

Anti-tumor Activity of Novel Nuclear Export Inhibitors (neis) in Multiple Murine Leukemia Models

Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia

Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling

Dual PI3K/mTOR inhibitor NVP‐BEZ235 decreases the proliferation of doxorubicin‐resistant K562 cells

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition

Mechanistic insights on cytotoxicity of KOLR, Cinnamomum pauciflorum Nees leaf derived active ingredient, by targeting signaling complexes of phosphodiesterase 3B and rap guanine nucleotide exchange factor 3